In-vivo biocompatibility evaluation of stents coated with a new biodegradable elastomeric and functional polymer

Coronary Artery Disease

Volumn 13, Issue 4, 2002, Pages 237-241

  Lee, Seung H ^a   Szinai, Istvan ^a   Carpenter, Kenneth ^a   Katsarava, Ramaz ^a   Jokhadze, Giuli ^a   Chu, Chih Chang ^a   Huang, Yanming ^a   Verbeken, Eric ^a   Bramwell, Orville ^a   De Scheerder, Ivan ^a   Hong, Mun K ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Angioplasty; Coronary artery disease; Polymer; Restenosis; Stent

Indexed keywords

COPOLYMER; ELASTOMER; POLYESTER; POLYESTERAMIDE; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ANGIOPLASTY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; SWINE;

ABSORBABLE IMPLANTS; ANIMALS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERIOSCLEROSIS; EVALUATION STUDIES; POLYMERS; RECURRENCE; STENTS; SWINE;

EID: 18544388087     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200206000-00006     Document Type: Article

References (20)

1. Lindsay J Jr, Hong MK, Pinnow E, Pichard AD. Effects of intraluminal coronary stents on the frequency of coronary artery bypass grafting after unsuccessful percutaneous transluminal coronary revascularization. Am J Cardiol 1996; 77:647-649.
2. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MR Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331:496-501.
3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331:489-495.
4. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967-1971.
5. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91:1676-1688.
6. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting. N Engl J Med 1998; 339:1665-1671.
7. Hardhammar PA, van Beusekom HM, Emanuelsson HU, Hofma SH, Albertsson PA, Verdouw PD, et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996; 93:423-430.
8. Serruys PW, Emanuelsson H, van der Giessen W, Lunn AC, Kiemeney F, Macaya C, et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries: early outcome of the BENESTENT-II pilot study. Circulation 1996; 93:412-422.
9. Kobayashi Y, De Gregorio J, Kobayashi N, Akiyama T, Reimers B, Finci L, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651-659.
10. Akiyama T, Moussa I, Reimers B, Ferraro M, Kobayashi Y, Blengino S, et al. Angiographic and clinical outcome following coronary stenting of small vessels. A comparison with coronary stenting of large vessels. J Am Coll Cardiol 1998; 32:1610-1618.
11. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid AS, Mehran R, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32:584-589.
12. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992; 20:467-474.
13. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong SC, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94:35-43.
14. Fajadet J, Perin M, Hayashi EB, Colombo A, Schuler G, Barragan P, et al. 210-day follow-up of the RAVEL study: a randomized study with the sirolimus-eluting BX VELOCITY balloon expandable stent in the treatment of patients with de novo native coronary artery lesions [abstract]. J Am Coll Cardiol 2002; 39(suppl A):20A.
15. Park SJ, Shim WH, Ho DS, Raizner A, Park SW, Kim JJ, et al. The clinical effectiveness of paclitaxel-coated coronary stents for the reduction of restenosis in the ASPECT trial [abstract]. Circulation 2001; 104(Suppl II):II-464.
16. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HMM, Serruys PW, Holmes DR Jr, et al. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation 1996; 94:1690-1697.
17. Bakker D, van Blitterswijk CA, Daems WT, Grote JJ. Biocompatibility of six elastomers in vitro. J Biomed Mater Res 1988; 22:423-439.
18. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997; 29:808-816.
19. Hong MK, Kornowski R, Bramwell O, Ragheb AO, Leon MB. Paclitaxel-coated Gianturco-Roubin® stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 2001; 12:513-515.
20. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet EA, Verdouw PD, Serruys PW, et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000; 83:338-345.